Viking Therapeutics (VKTX) Non Operating Income (2014 - 2026)
Viking Therapeutics (VKTX) posted Non Operating Income of $4.5 million for Q2 2026, down 21.64% sequentially from $5.8 million in Q1 2026, and down 49.68% YoY from $9.0 million in Q2 2025.
Viking Therapeutics (VKTX) Non Operating Income (2014 - 2026) Analysis & Trends
Viking Therapeutics has reported Non Operating Income for 13 years, with the latest figure at $4.5 million in Q2 2026.
- Quarterly Non Operating Income fell 49.68% year-over-year to $4.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $25.2 million (down 39.06% YoY) and the FY2025 annual result came in at $33.7 million, down 17.67% from the prior year.
- Non Operating Income retreated to $4.5 million in Q2 2026 per VKTX's latest filing, from $5.8 million in the prior quarter.
- Over five years, Non Operating Income peaked at $11.8 million in Q2 2024 and troughed at $154000.0 in Q1 2022.
- A 5-year average of $5.6 million and a median of $5.3 million in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2026: Non Operating Income soared 1697.23% in 2023, then plunged 49.68% in 2026.
- Over 5 years, Non Operating Income stood at $732000.0 in 2022, then surged by 542.9% to $4.7 million in 2023, then jumped by 130.43% to $10.8 million in 2024, then tumbled by 35.13% to $7.0 million in 2025, then sank by 35.39% to $4.5 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $4.5 million, $5.8 million, and $7.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - | 4.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.55 Mn |
| Mar 31, 2026 | 5.80 Mn |
| Dec 31, 2025 | 7.04 Mn |
| Sep 30, 2025 | 7.77 Mn |
| Jun 30, 2025 | 9.03 Mn |
| Mar 31, 2025 | 9.86 Mn |
| Dec 31, 2024 | 10.84 Mn |
| Sep 30, 2024 | 11.53 Mn |
| Jun 30, 2024 | 11.82 Mn |
| Mar 31, 2024 | 6.75 Mn |
| Dec 31, 2023 | 4.71 Mn |
| Sep 30, 2023 | 4.73 Mn |
| Jun 30, 2023 | 4.55 Mn |
| Mar 31, 2023 | 1.03 Mn |
| Dec 31, 2022 | 732,000.00 |
| Sep 30, 2022 | 450,000.00 |
| Jun 30, 2022 | 253,000.00 |
| Mar 31, 2022 | 154,000.00 |
| Dec 31, 2021 | 159,000.00 |
| Sep 30, 2021 | 125,000.00 |